Slide 1: Second Quarter Fiscal Year 2025 Earnings Presentation
AngioDynamics Second Quarter Fiscal Year 2025 Earnings Presentation January 8, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: FY Q2 2025 Key Takeaways
FY Q2 2025 Key Takeaways Continued commercial and operational execution positions AngioDynamics to drive accelerated, profitable growth moving forward CONTINUED COMMERCIAL EXECUTION • 9% YoY pro forma total revenue growth • MedTech segment pro forma revenue growth of 25% YoY • Auryon sales of $13.7
Slide 4: Q2 FY 2025 Pro Forma Financial Snapshot
Q2 FY 2025 Pro Forma Financial Snapshot Net Sales Segment Revenue Contribution $73.0 Q2 24 Q2 25 $66.9 38% $31.5 25.0% 43% $25.2 Pro Forma Growth 57% 62% Med Device Med Tech Med Device Med Tech (0.4)% $41.7 $41.5 Pro Forma Growth Segment Gross Margin Q2 24 Q2 25 47.8% 63.7% Med Device Med Tech Med D
Slide 5: YTD FY 2025 Pro Forma Financial Snapshot
YTD FY 2025 Pro Forma Financial Snapshot Net Sales Segment Revenue Contribution $140.5 YTD 24 YTD 25 $133.6 $51.0 $59.5 38% 16.8% 42% Pro Forma Growth 62% 58% Med Device Med Tech Med Device Med Tech $82.6 (2.0)% $81.0 Pro Forma Growth Segment Gross Margin YTD 24 YTD 25 48.0% 63.5% Med Device Med Tec
Slide 6: Med Tech - Auryon
Med Tech - Auryon Period Sales YoY Growth Q2 2025 $13.7M 21.8% YTD 2025 $27.4M 23.3% • Cumulative sales of over $150M since launch in Sept 2020 • Continued penetration into hospital setting • Launched the 1.7mm Catheter in Q1 FY25 • European CE Mark approval in Q1 FY25 6
Slide 7: Med Tech - Thrombus Management
Med Tech - Thrombus Management 2Q 2025 Sales YoY Growth YTD 2025 Sales YoY Growth AngioVac $8.1M 50.7% AngioVac $13.9M 18.9% AlphaVac $2.5M 33.3% AlphaVac $4.7M 27.4% Total Mech Thromb. $10.6M 46.2% Total Mech Thromb. $18.6M 20.9% Unifuse $1.3M 22.7% Unifuse $2.4M 11.3% Total Thrombus Mgmt. $11.9M 4
Slide 8: Med Tech - NanoKnife
Med Tech - NanoKnife 2Q 2025 Sales YoY Growth YTD 2025 Sales YoY Growth Disposables $5.0M 23.1% Disposables $9.1M 8.8% Capital $1.0M (39.7)% Capital $2.0M (29.4)% Total $6.0M 4.9% Total $11.1M (0.9)% • Received CPT Category 1 Codes (Oct. 2024), which is expected to streamline reimbursement for healt
Slide 9: Med Device
Med Device 2Q 2025 Sales YoY Growth YTD 2025 Sales YoY Growth Core Peripheral $19.0M (1.2%) Core Peripheral $37.4M (1.1%) Venous / EVLT $7.4M 1.6% Venous / EVLT $13.5M 1.1% Ports $8.8M (1.8%) Ports $18.2M 1.4% Solero Microwave $4.7M 2.6% Solero Microwave $8.9M (13.8%) Alatus and Isoloc Balloons $1.0
Slide 10: Fiscal Year 2025 Guidance
Fiscal Year 2025 Guidance Metric Prior Guidance Updated Guidance Full Year Net Sales $282 - $288 million $282 - $288 million Med Tech Net Sales 10 – 12% YoY growth 12 – 15% YoY growth Med Device Net Sales 1 – 3% YoY growth Flat Gross Margin 52 - 53% 52 - 53% Adjusted EBITDA ($2.5) - $0 million $1.0
Slide 11: Fiscal Year 2025 Catalysts
Fiscal Year 2025 Catalysts Auryon • Received CE Mark in Q1 FY2025 • Conducting limited market release in EU before transitioning to full market release • Full market release expected in the first quarter of calendar 2025 • Continuing to increase penetration in the hospital setting in the U.S. AlphaV
Slide 12: Appendix
Appendix 12
Slide 13: Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements
Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements (in thousands, except per share data) (in thousands, except per share data) 13
Slide 14: Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted Net Loss and EPS
Reconciliation of GAAP Net Income (Loss) Reconciliation of Net Income (Loss) to to Non-GAAP Adjusted Net Loss and EPS Adjusted EBITDA (in thousands, except per share data) (in thousands, except per share data) 14
Slide 15: Reconciliation of Non-GAAP Pro Forma Net Loss to Adjusted Pro Forma Net Loss and EPS
Reconciliation of Non-GAAP Pro Forma Reconciliation of Non-GAAP Pro Forma Net Loss to Adjusted Pro Forma Net Loss Net Loss to Adjusted Pro Forma EBITDA and EPS (in thousands, except per share data) (in thousands, except per share data) 15
Slide 16: Detail of Acquisition, Restructuring and Other Items, net
Detail of “Acquisition, Restructuring and Other Items, net” 16
Slide 17: Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category
Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category (in thousands) (in thousands) 17